Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Galapagos NV (NQ: GLPG )

130.40 USD +1.57 (+1.22%)
Official Closing Price Updated: 4:30 PM EDT, Oct 19, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 511,700
Open 132.82
Bid (Size) 115.05 (1)
Ask (Size) 152.10 (1)
Prev. Close 128.83
Today's Range 129.85 - 133.69
52wk Range 112.00 - 274.03
Shares Outstanding 51,337,763
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
From GlobeNewswire News Releases
Oxurion NV Business Update – Q3 2020
From GlobeNewswire News Releases

Performance

YTD
-38.52%
-38.52%
1 Month
-6.64%
-6.64%
3 Month
-38.94%
-38.94%
6 Month
-39.58%
-39.58%
1 Year
-17.22%
-17.22%

More News

Read More
Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
From GlobeNewswire News Releases
PHASE 2B/3 TRIAL SHOWS EFFICACY OF FILGOTINIB FOR THE INDUCTION AND MAINTENANCE OF REMISSION IN MODERATELY AND SEVERELY ACTIVE ULCERATIVE COLITIS
From GlobeNewswire News Releases
Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis
From Business Wire News Releases
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial
From GlobeNewswire News Releases
EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ACTIVE RHEUMATHOID ARTHRITIS
From GlobeNewswire News Releases
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
From Business Wire News Releases
Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
From GlobeNewswire News Releases
Galapagos increases share capital through subscription right exercises
From GlobeNewswire News Releases
Oxurion NV Business Update - H1 2020
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]